DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20212081

Study on antihyperglycemic effect of bromocriptine in dexamethasone induced hyperglycemic wistar rats

Rekha M. B., Basavaraj Bhandare, Satyanarayana V., Hemamalini M. B.

Abstract


Background: Diabetes mellitus is a chronic metabolic disorder that develops due to insulin deficiency or insulin resistance. Recent animal and human studies have reported bromocriptine to be effective in the management of type 2 diabetes mellitus. The present study was done to evaluate the antihyperglycemic effect of bromocriptine in dexamethasone induced hyperglycemic rats.

Methods: Male wistar rats were used and divided into 5 groups. Dexamethosone was used to induce hyperglycemia in group B-E. Group A was the untreated control group, group B was the standard control group, group C was the oral 10 mg/kg of bromocriptine dissolved in 0.9% normal saline, group D was the oral 20 mg/kg metformin dissolved in 0.9% normal saline, group E was the oral 10 mg/kg bromocriptine+20 mg/kg metformin dissolved in 0.9% normal saline. Fasting blood glucose, post prandial blood glucose and body weight was estimated on day 1, 15, 30.

Results: It was seen that dexamethasone induced hyperglycemia and increase in body weight in male wistar rats, which were significantly controlled by oral bromocriptine and bromocriptine with metformin combination.

Conclusions: Results obtained from this study showed that bromocriptine can be a promising drug with novel mechanism to treat type 2 diabetes mellitus.


Keywords


Bromocriptine, Wistar rats, Diabetes mellitus, Metformin

Full Text:

PDF

References


International Diabetes Federation. IDF Diabetes Atlas, 8th ed. Brussels, Belgium: International Diabetes Federation; 2017

Cho NH, Shaw JE, Karuranga S, Huang Y, Fernandes JDR, Ohlrogge AW. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projection for 2045. Diabetes Res Clin Pract. 2018:138:271-81.

Shivaprasad C, Kalra S. Bromocriptine in type 2 diabetes mellitus. Ind J Endocr Metabol. 2011:15(1):17-24.

Maharajan R, Gupta K, Kapoor V. A systematic account of pathogenesis, diagnosis and pharmacotherapy of metabolic syndrome. Things we need to know. Int J Pharmacol. 2010:6(4):338-45.

Norris SL, Zhang X, Avanell A, Gregg E, Schmid CH, Kim C, et al. Efficacy of pharmacotherapy for weight loss in adults with type-2 diabetes mellitus: a meta-analysis. Arch Intern Med. 2004:164(13):1395-404.

Kerry JL, Timpe EM, Petkewicz KA. Bromocriptine mesylate for glycemic management in type-2 diabetes mellitus. Ann Pharmacother. 2010;44(11):1777-85.

Via MA, Chandra H, Araki T, Potenza MV, Skamagas M. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type-2 diabetes. Diabetes Metab Syndr Obes. 2010;3:43-8.

Defronzo RA. Bromocriptine: A sympatholytic D2 dopamine agonist for the treatment of type2 diabetes. Diabet Care. 2011;34(4):789-94.

Powers AC, D’Alessio D. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: Brunton Medical; 2018: 1237-73.

Cincotta AH, Meier AH. Bromocriptine reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care. 1996;19(6):667-70.